المؤلفون: Rja Oomen, Joost L. Boormans, P J Ausems, S D Bos, Henk G. van der Poel, Henk B. Luiting, André N. Vis, Deric K E van der Schoot, Katja K.H. Aben, L Korsten, M A Noordzij, A van der West, T. van Doeveren, K J Lentjes, B P Schrier, P J Stelwagen, E L Koldewijn, M M Hobijn, Sytse C. van Beek, N van Ginkel, D M Somford, K T Buddingh, B.P. Wijsman, P van Zanten, Jakko A. Nieuwenhuijzen, H Bickerstaffe, K Dekker, M Braam, S Claus, S van der Meer, R I Nooter, O S Klaver, Jgh van Roermund, Smh Einerhand, A Lenting, Cpam Berger, M Jaspers-Valentijn, LA Grondhuis Palacios, D Baselmans, Tjn Hermans, H Roshani, T J Arends, Florentien J Hinsenveld, Ama Stroux, Caw Notenboom, M A van der Slot, A Berrens, J de Rooij, E J van Gennep, Lmcl Fossion, S H van Huystee, Wakm Windt

المساهمون: Urology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, Other Research, VU University medical center, MUMC+: MA AIOS Urologie (9), MUMC+: MA Urologie (9), RS: FHML non-thematic output, Radiotherapy

المصدر: Urologic Oncology-Seminars and Original Investigations, 40, 60.e1-60.e9
Urologic Oncology: Seminars and Original Investigations. Elsevier Inc.
Urologic oncology-seminars and Original Investigations, 40(2), 60.e1-60.e9. Elsevier Science
Hinsenveld, F J, Boormans, J L, van der Poel, H G, van der Schoot, D K E, Vis, A N, Aben, K K H, Arends, T J, Ausems, P J, Baselmans, D, Berger, C P A M, Berrens, A, Bickerstaffe, H, Bos, S D, Braam, M, Buddingh, K T, Claus, S, Dekker, K, van Doeveren, T, Einerhand, S M H, Fossion, L M C L, van Gennep, E J, van Ginkel, N, Palacios, L A G, Hermans, T J N, Hobijn, M M, van Huystee, S H, Jaspers-Valentijn, M, Klaver, O S, Koldewijn, E L, On behalf of the Dutch Cystectomy Snapshot Group, Korsten, L, Lenting, A, Lentjes, K J, Luiting, H B, van der Meer, S, Nieuwenhuijzen, J A, Noordzij, M A, Nooter, R I, Notenboom, C A W, Oomen, R J A, van Roermund, J G H, de Rooij, J, Roshani, H, Schrier, B P, van der Slot, M A, Somford, D M, Stelwagen, P J, Stroux, A M A, van der West, A, Wijsman, B P, Windt, W A K M, van Zanten, P & van Beek, S C 2021, ' Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands ', Urologic Oncology: Seminars and Original Investigations . https://doi.org/10.1016/j.urolonc.2021.06.018
Urologic Oncology-Seminars and Original Investigations, 40, 2, pp. 60.e1-60.e9
Urologic Oncology: Seminars and Original Investigations, 40(2), 60.e1-60.e9. Elsevier Inc.

مصطلحات موضوعية: Male, Surgical margin, medicine.medical_specialty, Survival, Robot, Urology, medicine.medical_treatment, Cystectomy, All institutes and research themes of the Radboud University Medical Center, Robotic Surgical Procedures, SDG 3 - Good Health and Well-being, Muscle invasive, medicine, Humans, Stage (cooking), Neoadjuvant therapy, Aged, Netherlands, Retrospective Studies, OUTCOMES, Bladder cancer, Proportional hazards model, business.industry, Hazard ratio, Retrospective cohort study, Robotics, medicine.disease, Survival Analysis, Urinary Bladder Neoplasms, Oncology, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Female, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::271babd5374478c875b9eed3e1320aaf
https://doi.org/10.1016/j.urolonc.2021.06.018

المؤلفون: Einerhand SMH; Department of Medical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Heijden MS; Department of Medical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: ms.vd.heijden@nki.nl.

المصدر: European urology focus [Eur Urol Focus] 2024 Aug 29. Date of Electronic Publication: 2024 Aug 29.

نوع المنشور: Journal Article; Practice Guideline

بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101665661 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-4569 (Electronic) Linking ISSN: 24054569 NLM ISO Abbreviation: Eur Urol Focus Subsets: MEDLINE

المؤلفون: Einerhand SMH; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Zuur LG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Wondergem MJ; Department of Nuclear Medicine, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Boellaard TN; Department of Radiology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., Barwari K; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., van Leeuwen PJ; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands., van Rhijn BWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Department of Urology, Caritas St Josef Medical Centre, University of Regensburg, 93053 Regensburg, Germany., Mertens LS; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.

المصدر: Journal of clinical medicine [J Clin Med] 2023 May 09; Vol. 12 (10). Date of Electronic Publication: 2023 May 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE

المؤلفون: Einerhand SMH; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands., Voskuilen CS; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands., van de Putte EEF; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands., Donswijk ML; Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Bruining A; Department of Radiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van der Heijden MS; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Mertens LS; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands., Hendricksen K; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands., Vegt E; Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Rhijn BWG; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands.; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.

المصدر: Bladder cancer (Amsterdam, Netherlands) [Bladder Cancer] 2023 Mar 31; Vol. 9 (1), pp. 49-57. Date of Electronic Publication: 2023 Mar 31 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101668567 Publication Model: eCollection Cited Medium: Internet ISSN: 2352-3735 (Electronic) Linking ISSN: 23523727 NLM ISO Abbreviation: Bladder Cancer Subsets: PubMed not MEDLINE

المؤلفون: Einerhand SMH; Department of Surgical Oncology (Urology), Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands., van Dorp J; Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Molecular Carcinogenesis, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Heijden MS; Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Molecular Carcinogenesis, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands., van Rhijn BWG; Department of Surgical Oncology (Urology), Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany. Electronic address: basvanrhijn@hotmail.com.

المصدر: European urology [Eur Urol] 2023 Jan; Vol. 83 (1), pp. 91-92. Date of Electronic Publication: 2022 Oct 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Transitional Cell*/pathology , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/surgery , Urinary Bladder Neoplasms*/pathology, Humans ; Cisplatin ; B7-H1 Antigen ; Neoadjuvant Therapy

المؤلفون: Einerhand SMH; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., van Dijk N; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Dorp J; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Feijter JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Montfoort ML; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Kamp MW; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., Schaake EE; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boellaard TN; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hendricksen K; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Heijden MS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Rhijn BWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.

المصدر: International journal of cancer [Int J Cancer] 2022 Dec 01; Vol. 151 (11), pp. 2004-2011. Date of Electronic Publication: 2022 Jun 10.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Transitional Cell*/drug therapy , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology, Antineoplastic Combined Chemotherapy Protocols ; Carboplatin ; Cisplatin ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy ; Ipilimumab/therapeutic use ; Neoadjuvant Therapy ; Nivolumab/therapeutic use ; Platinum/therapeutic use

المؤلفون: Einerhand SMH; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., van Dijk N; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Heijden MS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Rhijn BWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.

المصدر: International journal of cancer [Int J Cancer] 2022 Nov 15; Vol. 151 (10), pp. 1849-1850. Date of Electronic Publication: 2022 Aug 10.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Transitional Cell* , Urinary Bladder Neoplasms*/drug therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Immunotherapy ; Neoadjuvant Therapy ; Platinum/therapeutic use

المؤلفون: Einerhand SMH; Department of Surgical Oncology (Urology), The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Black AJ; Vancouver Prostate Centre, Vancouver, Canada., Zargar H; Department of Urology, Western Health, Melbourne, Australia., Fairey AS; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.; University of Alberta, Edmonton, AB, Canada., Dinney CP; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA., Mir MC; Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain., Krabbe LM; Department of Urology, University of Münster, Münster, Germany., Cookson MS; Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA., Jacobson NE; University of Alberta, Edmonton, AB, Canada., Montgomery JS; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA., Vasdev N; Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK.; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK., Yu EY; Division of Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, USA., Xylinas E; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital New York, New York, NY, USA., Kassouf W; Department of Surgery (Division of Urology), McGill University Health Centre, Montreal, QC, Canada., Dall'Era MA; Department of Urology, David Medical Center, University of California at David, Sacramento, CA, USA., Sridhar SS; Princess Margaret Hospital, Toronto, ON, Canada., McGrath JS; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK., Aning J; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK.; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK., Shariat SF; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital New York, New York, NY, USA.; Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria., Wright JL; Division of Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, USA., Thorpe AC; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK., Morgan TM; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA., Holzbeierlein JM; Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA., Bivalacqua TJ; Division of Urology, University of Pennsylvania, Pennsylvania, PA, USA., North S; Cross Cancer Institute, Edmonton, AB, Canada., Barocas DA; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Lotan Y; Department of Urology, University of Texas Southern Medical Center, Dallas, TX, USA., Grivas P; Division of Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, USA., Garcia JA; Department of Medicine, Case Comprehensive Cancer Center, Cleveland, USA., Stephenson AJ; Division of Urology, Rush University Medical Center, Chicago, IL, USA., Shah JB; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA., Daneshmand S; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA., Zargar-Shoshtari K; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Spiess PE; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., van Rhijn BWG; Department of Surgical Oncology (Urology), The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany., Black PC; Vancouver Prostate Centre, Vancouver, Canada., Mertens LS; Department of Surgical Oncology (Urology), The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. l.mertens@nki.nl.

المصدر: World journal of urology [World J Urol] 2022 Nov; Vol. 40 (11), pp. 2707-2715. Date of Electronic Publication: 2022 Sep 28.

نوع المنشور: Multicenter Study; Journal Article

بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 8307716 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-8726 (Electronic) Linking ISSN: 07244983 NLM ISO Abbreviation: World J Urol Subsets: MEDLINE

مواضيع طبية MeSH: Cystectomy* , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/surgery, Humans ; Neoadjuvant Therapy/methods ; Cisplatin/therapeutic use ; Carboplatin ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Muscles ; Retrospective Studies ; Gemcitabine

المؤلفون: Voskuilen CS; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Gennep EJ; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Leiden University Medical Center, Leiden, The Netherlands., Einerhand SMH; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Vegt E; Department of Nuclear Medicine, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Donswijk ML; Department of Nuclear Medicine, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Bruining A; Department of Radiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van der Poel HG; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Horenblas S; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Hendricksen K; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Rhijn BWG; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany., Mertens LS; Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: l.mertens@nki.nl.

المصدر: European urology oncology [Eur Urol Oncol] 2022 Jun; Vol. 5 (3), pp. 366-369. Date of Electronic Publication: 2021 Feb 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Fluorodeoxyglucose F18* , Urinary Bladder Neoplasms*/diagnostic imaging , Urinary Bladder Neoplasms*/therapy, Humans ; Lymphatic Metastasis ; Neoplasm Recurrence, Local ; Positron Emission Tomography Computed Tomography/methods ; Retrospective Studies

المؤلفون: Lonati C; Department of Urology, Spedali Civili di Brescia, piazzale Spedali Civili 1, 25123, Brescia, Italy. chiara.lonati@libero.it.; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. chiara.lonati@libero.it., Afferi L; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland., Mari A; Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy., Minervini A; Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy., Krajewski W; Department of Urology and Oncological Urology, Wrocław Medical University, Wrocław, Poland., Borghesi M; Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy., Schulz GB; Department of Urology, Ludwig-Maximilians-University, Munich, Germany., Rink M; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Montorsi F; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.; University Vita-Salute San Raffaele, Milan, Italy., Briganti A; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.; University Vita-Salute San Raffaele, Milan, Italy., Colombo R; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Martini A; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Necchi A; University Vita-Salute San Raffaele, Milan, Italy.; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy., Contieri R; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Hurle R; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Umari P; Division of Surgery and Interventional Science, University College London, London, UK., Zamboni S; Department of Urology, Spedali Civili di Brescia, piazzale Spedali Civili 1, 25123, Brescia, Italy., Simeone C; Department of Urology, Spedali Civili di Brescia, piazzale Spedali Civili 1, 25123, Brescia, Italy., Soria F; Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy., Marra G; Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy., Gontero P; Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy., Teoh JY; Department of Surgery, Prince of wales Hospital, The Chinese University of Hong Kong, Hong Kong, China., Klatte T; Department of Urology, Charité, Universitätsmedizin Berlin, Berlin, Germany., Bajeot AS; Department of Urology, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France., Roumiguié M; Department of Urology, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France., Rouprêt M; GRC 5 Predictive Onco-Uro, AP-HP, Urology, Sorbonne University, Pitie-Salpetriere Hospital, 75013, Paris, France., Masson-Lecomte A; APHP, Department of Urology, Hôpital Saint Louis, Université de Paris, Paris, France., Laukhtina E; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria., Valiquette AS; Department of Urology, Fundación Instituto Valenciano de Oncologia, Valencia, Spain., Mir MC; Department of Urology, Fundación Instituto Valenciano de Oncologia, Valencia, Spain., Antonelli A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy., Einerhand SMH; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Hendricksen K; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Carando R; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.; Clinica Luganese Moncucco, Lugano, Switzerland.; Clinica S.Anna, Swiss Medical Group, Sorengo, Switzerland.; Clinica Santa Chiara, Locarno, Switzerland., Fankhauser CD; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland., Baumeister P; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland., Mattei A; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland., Shariat SF; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.; Department of Urology, Weill Cornell Medical College, New York, NY, USA.; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic., Moschini M; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

مؤلفون مشاركون: European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group

المصدر: World journal of urology [World J Urol] 2022 May; Vol. 40 (5), pp. 1167-1174. Date of Electronic Publication: 2022 Feb 26.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 8307716 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-8726 (Electronic) Linking ISSN: 07244983 NLM ISO Abbreviation: World J Urol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Squamous Cell*/pathology , Carcinoma, Squamous Cell*/surgery , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/surgery, BCG Vaccine/therapeutic use ; Cystectomy ; Female ; Humans ; Immunotherapy ; Male ; Neoplasm Invasiveness/pathology ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Retrospective Studies ; Urinary Bladder/pathology